http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011162557-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e68f5df8b9842356701c0522dc9933ea |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 |
| filingDate | 2011-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_641a635fbdb469c9fd5713cbaafdd88f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dcdbfa9294afb0c1412bdfcbcbb553d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95cf65f5eb7130d99480db2b36b2e458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_160a76c061419c1ba959afd993793a8c |
| publicationDate | 2011-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011162557-A |
| titleOfInvention | Combinations of sedatives and neurotransmitter modulators, methods for improving sleep quality, and methods for treating depression |
| abstract | One aspect of the present invention relates to a pharmaceutical composition containing two or more active substances that can be used, for example, for the treatment of insomnia and / or depression when taken together. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT 2A modulator, or a dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention relates to a method for treating sleep disorders, a method for treating insomnia, comprising co-administering a GABA receptor-modulating compound and an SRI, NRI, 5-HT 2A modulator or DRI to a patient in need thereof, It also relates to a method for treating depression, a method for enhancing antidepressant treatment, a method for exerting a dose-saving effect, a method for reducing recurrence of depression, a method for improving the efficacy of an antidepressant treatment, or a method for improving the tolerance of an antidepressant treatment. [Selection] Figure 3 |
| priorityDate | 2003-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1391.